My name is David, and I will be your conference call facilitator this afternoon. At this time, I would like to welcome everyone to Envista Holdings Corporation's Fourth Quarter 2021 Earnings Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. I'll now turn the call over to Mr. Stephen Keller, Vice President of Investor Relations of Envista Holdings. Mr. Keller, you may begin your conference call.

Thank you. Hello, and thanks for joining us on the call today. With us here in the room are Amir Aghdaei, our President and Chief Executive Officer; and Howard Yu, our Chief Financial Officer. I want to point out that the earnings release, the slide presentation supplementing today's call and the reconciliation and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are available on the Investors section of our website, www.envistaco.com. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events and Presentations. It will remain archived until our next quarterly call. As announced on January 3, 2022, we have closed the divestiture of our KaVo Treatment Unit and Instrument business. For the fourth quarter and the full year 2021, the results of this business are reflected as discontinued operations in our financial statements as required by generally accepted accounting principles. Additionally, the financial statements to be included in our 10-K for the fiscal 2021 will reflect KaVo Treatment Unit and Instrument business as discontinued operations as required by GAAP. All references in these remarks and accompanying presentation to earnings, revenues and other company-specific financial metrics relate only to the continuing operations of Envista's business except for cash flow measures. During the presentation, we will describe some of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these materials and supplemental materials to company-specific financial metrics relate to the fourth quarter of 2021, and all references to period-to-period increases or decreases in financial metrics are year-over-year. We may also describe certain products and devices that have applications submitted and pending certain regulatory approvals or are available only in certain markets. During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe, anticipate or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made and we do not assume any obligation to update any forward-looking statements, except where as required by law. With that, I'd like to turn the call over to Amir.

Thank you, Stephen, and welcome, everyone, to Envista's fourth quarter 2021 earnings call. I want to begin by thanking our employees for delivering an outstanding 2021. Despite a challenging macro environment with COVID-related headwinds, numerous supply chain disruptions, and significant inflation, our employees deliver outstanding results by partnering with dental professionals to improve the lives of patients and expand access to our care. Our employees' passion and dedication allowed us to deliver on our commitments to our clinicians and our shareholders. For the full year 2021, we delivered core revenue growth of 29% over 2020 and 8.9% over 2019. While we did see some softening in patient volumes in late Q4, continuing into January, our view is that this is primarily related to staff shortages and patient cancellations driven by Omicron variant and increasing rates of infection. As infections peak, we believe patient volumes will come back with limited loss of demand. We're still growing significantly above pre-pandemic levels and we continue to benefit from the repositioning of our portfolio, our improved commercial execution and our long-term investments in innovation. For 2021, our adjusted EBITDA margin was 19.7%, representing a greater than 650 basis point improvement over the pandemic impacted 2020 and delivering over 400 basis points of improvement versus 2019. Before I turn it over to Howard to discuss our fourth quarter results, I want to provide more color on our progress towards our long-term priorities of transforming our portfolio, accelerating our growth and expanding our operating margins. 2021 was a transformational year for Envista. We took significant steps to reorient our portfolio to higher growth, higher margin segments of the dental industry where we can create competitive, sustainable advantage. We announced and completed the divestiture of the KaVo Treatment Unit and Instrument's business does shift in our business…

Thanks, Amir. Before we begin, I'd like to remind you that our fourth quarter results are based on continuing operations reflecting the sale of our KaVo Treatment Unit and Instruments business. Accordingly, the quarterly results of KaVo Treatment Unit and Instruments business are reported as discontinued operations. Fourth quarter sales increased 5.8% to $651.8 million. Reported sales were negatively impacted by 0.5% due to foreign currency exchange rates and further negatively impacted by 0.3% related to other discontinued products. Our core sales growth was 6.6% compared to fourth quarter of 2020. Our year-over-year growth reflects solid growth from our orthodontic, implant and imaging businesses, which was offset by temporary weakness in our Infection Prevention business. Geographically, Western Europe grew 15%, while North America grew 1.8%, dragged down by its greater exposure to Infection Prevention. Overall, emerging markets continue to expand from pandemic lows, growing 12.8% despite relative weakness in China driven by localized pandemic lockdown. Our fourth quarter adjusted gross margin from continuing operations was 57.1%, increasing by 60 basis points compared to the prior year due to higher volume, favorable product mix and productivity initiatives across our portfolio. The adjusted Q4 2021 EBITDA margin was 18.5%, which is 110 basis points lower than in Q4 of 2020. As expected, in Q4, we continued to invest in our long-term innovation while increasing spend on travel and in-person customer-facing activities with the continued easing of the pandemic-related lockdowns. Our adjusted EBITDA was also negatively impacted by approximately $4 million in stranded costs related to the sale of the KaVo Treatment Unit and Instruments business. We expect to address the estimated greater than $10 million of annual stranded costs in 2022. Our fourth quarter adjusted diluted EPS was $0.46 from continuing operations compared to $0.43 in the comparable period of the prior…

Thanks, Howard. We are pleased with our 2021 results and remain very optimistic about the future of the dental industry. Given our recent portfolio moves, we are now more focused on the faster-growing, higher-margin and most attractive segments within dental. We continue to work with our clinical partners to streamline their operations and improve patient care while expanding access to oral care around the world. Moving forward, our priorities remain the same. We will accelerate growth, expand our operating margin and continue to further transform our portfolio through active and disciplined capital deployment. Our intention is to be the leader in orthodontics, providing a differentiated and any grated suite of treatment options, including bracket and wires and clear aligners. Our comprehensive offering empowers orthodontics to provide the best treatment modality for each patient. Based on our broad portfolio and this powerful combination, we plan to triple our Spark business in the next three years while continuing to gain share in wire and brackets. We will further accelerate our growth in implants by leveraging our premium implant franchise to provide full solutions across the implant workflow, including regenerative and prosthetic offerings by leveraging our diagnostics and digital capabilities. We will continue to grow and broaden access to our highly profitable and differentiated consumables business. Finally, we will leverage our strength in imaging and diagnostics to build a digitally integrated workflows from diagnostics to treatment planning to execution for our clinical partners. We will continue to utilize our EBS heritage to both improve our execution and drive margin expansion. We are committed to delivering annual margin expansion. Finally, we continue to see significant opportunities to invest organically and inorganically. And we have the financial flexibility and management focus to further accelerate our growth trajectory. We have disciplined capital deployment and inorganic investments. As we continue in our journey to digitize, personalize and democratize the dental industry, we are excited about hosting our first Investor Summit, designed to highlight our unique and differentiated product portfolio and digitally integrated solutions. This event would bring together our historically popular Ormco Forum and Nobel Biocare Symposium with a brand-new technology track to create a three-track agenda designed to educate and train dental professionals in every aspect of dentistry united by our best-in-class customer experience and products. The progress we made this quarter and in 2021 is a direct reflection of our culture centered and continuous improvement and our commitment to our customers in the dental industry. Our purpose is to partner with dental professionals and improve patient lives by personalizing, digitizing and democratizing dental care. We're excited about our continued growth journey in 2022 and beyond.

Thanks, Amir. That concludes our formal comments. We are now ready for questions.

And we'll take our first question from Elizabeth Anderson with Evercore. Please go ahead, your line is open.

Hi guys, thanks so much and congrats on a nice quarter. Maybe to kick us off, Amir, can you talk – give us a little bit more details on the impact Omicron this time around? It seems like it was maybe a little bit, obviously, different than earlier wave, maybe either by different areas or sort of also as we go into January, how those trends have been continuing? Thanks.

Thank you, Elizabeth. What we saw at the end of Q4, the last two weeks of December, a lot of feedback from our partners in various DSOs and companies that we work with is a significant slowdown in the past, in the last two weeks of December. And that was purely because of the infection ramping up, increased rate of infection, a lot of cancellation as well as staff shortages. First, this trend continued in the first two weeks of January as well. What we are seeing now a ramp back up to normal demand and patient volumes. And we think that as infections move past the peak, we believe patient volumes would come back with limited loss of demand. Overall, really optimistic about underlying demand remain mindful of continued risk of COVID or we think that we are really centered in helping supporting our customers to manage through this challenging time. And we do not see that as being a major impact in our growth as we go throughout the year.

Thanks so much. And maybe the follow-up, Howard, I know you gave the guide for the full year with the first half versus second half margin differences in some of the details there. I was just thinking about maybe the demand profile. Can you – any more details you can share with us about sort of how you see demand progressing as we go through the year? And anything else that would be good to call out just in terms of the phasing of the quarters?

Sure, sure. Thanks for the question. Yes. As we indicated, we see the full year guide is growing 6% to 8% with the adjusted EBITDA margins north of 20%. If we talk about, let's say, Q1, with some of the slowdown that we saw very early on in the quarter, we expect mid-single-digit growth, core growth here in Q1 and high teens EBITDA, particularly as we work through some of the stranded costs as well as continue to fortify a lot of the investments that we're making. As Amir indicated, we're really pleased with where our Spark business is and we're prepared to go ahead and continue to invest in that business. And so you're seeing a little bit of softness there. But then throughout the year, I'd say, with each quarter, you're going to see improvements in our growth rates as well as our margins.

That’s helpful. Thanks.

We'll take our next question from Jeff Johnson with Baird. Please go ahead, your line is open.

Thank you. Hey, guys good afternoon. Two questions here for me. One, just on the price increases. We've confirmed with a couple of the dealers, you did take a price increase here at the start of the year. Seems like 2% to 3% kind of holding across most of consumables. Is that a fair way to think about it, one? And then two, is there any pricing power in any other parts of the portfolio? We've heard anecdotally some of the implant guys taking price increases? Would like to know what you're doing there maybe or anything else in the portfolio? Thanks.

So yes, Jeff, I don't think that – we don't – institute across-the-board price increases. Each of our opcos are taking appropriate pricing actions to drive growth while protecting and expanding our margins. Pricing should be seen as a tailwind, as you indicated. We have done some of that in some of our businesses. I would say that it wouldn't be limited just to the consumables piece. You mentioned implant, even as it relates to orthodontics as well we see that as being an opportunity. Longer term, I think we continue to believe that our focus on innovation is the key to maintaining and expanding average selling prices and margins as well as we look to drive growth.

Yes. All right. That's helpful. Thank you. And then, Amir, maybe on Spark, you hit that $100 million run rate earlier than I think any of us were expecting. It sounds like about $75 million for the full year and you're talking about now tripling that over three-years. So is that a fair way to think about it? $75 million in 2021 going to $225 million over the next three-years and what are you seeing just in the short run here? Have you – in clear aligners, I know you're in market share-taking position, so it's hard to see kind of a slowdown if there's been a pull forward or some discretionary spending dollars that aren't as strong this year as they might have been in the heat of last year. But just what are you seeing for the clear aligner demand side of the equation over the next few quarters? Thanks.

Yes, of course. Your calculation is not wrong. You are close to what we are seeing, not exactly those numbers, but it's not far off. We are – we have created, and we have talked about this continuously, a differentiated solution and it is really focused on a professional medtech segment of the market. And that has been proven that it is truly differentiated. People see the value of it, not only on the product itself, but on training, education and service and support and the way that we bring people up to speed and continue to support a movement. For sure, there has been some pull forward. But we don't expect that, that would have any impact in our ramp as we go forward. As you know very well, we started through a very phased approach of adding dentists every quarter and seeing them coming up to see that process has continued as we have gone forward. To give you a little bit of a feel both on the production as well as the number of dentists that are now using Spark as their primary clear aligner, we are seeing double-digit growth in the number of dentists, number of doctors that they're using. And it is across geographies. In fact, in Europe, our wrap is exceeding what we saw in North America. So we are pretty confident that what we have done, the approach that we have taken is working and some of the things that you're seeing in the market, it actually has proven the approach that we took showing a steady, make sure that we provide a differentiated solution is working. And we feel that's going to be the trend to continue as we go forward.

Thank you.

We'll next question from John Kreger with William Blair. Please go ahead. Your line is open.

Hey, thanks very much. Amir, could you talk a little bit more about the Carestream strategy? I'm curious, if you look at that installed base to what degree that those are sort of your customers already? Or are they kind of a new customer opportunity. And how is the integration at this point? Will you be up and running, let's say, with Spark and other solutions right away? Or should we assume that will take some time?

Hey, John, let me maybe – just a little bit of frame this on the IOS market first, and then I answer that question. We think this market is over $1 billion, is growing double digit. We think this market has above EBITDA compared to the rest of the product out there. And our estimates are that this is less than 15% penetrated. So there are some key numbers in there to think about. The business was about close to about $60 million last year. If you go back, take a look at it mathematically or since the introduction of 3600, 3700 and 3800, the Carestream has less than 10,000 installed base worldwide. So now take a look at the ramp that is taking place, the access that we can provide and integration with the DTX and then 3,400 salespeople that we have out there, access to geographies and DSOs. It gives us an opportunity to take this business and bring it to a different level, continue to invest in R&D and integrate it into our software. And then EBS plays such an important role in here to improve delivery, quality and margin over time. We have been looking at, as you well know, in this space for almost five or six years, and we found that Carestream IOS has and meets many of those qualifications that we have been looking for. It's a great product. Hardware is just really good, and as a suite of software that is already in place. And where we can add value is really complementary to what Carestream has done in the past. I can't comment a lot until this deal is completely close, but we expect an integration, the DTX to take place as soon as the deal is closed in Q2. And we expect a ramp throughout the year in various geographies as we go forward. We think impact in the next few years is going to be over 50 basis points of core growth to our run rate as well as over 40 basis points of margin expansion. So it is a really complementary business that is going to help us not only on its core as a product but also in our intention of digitizing the industry as a whole.

Sounds great. Thanks for all the detail.

Thank you, John.

We’ll take our next question from Jon Block with Stifel. Please go ahead. Your line is open.

Hey, Jon.

Hey, good afternoon. Just first one on N1. And if you guys can just talk to the rollout cadence in the U.S. and will Omicron delay the pace of that rollout a little bit? And then maybe just to level set as a tack on, I think previously, you guys have talked about 300 doctors trained in Europe on N1, what’s that off of a base of just so we can sort of size up where you are in the training process in Europe since it was obviously approved over there several quarters ago? And then I’ll ask a follow-up.

Yes, I’m happy to give you that, Jon. Exactly correct. We started training in Europe. And we have several hundred dentists that they are now using actively N1. Actively, in our opinion, is more than onetime purchases that are beginning to transition some of their current usage to N1, and they’re beginning to see the outcome of that. And they’re giving us some really good feedback. Our approach in the U.S. is very similar to what we did with the Spark. We’re going to have to create these cohorts of five to 10 people in a smaller, safe setting. In fact, the first group is going to take place this weekend. We’re going to teach them, train them, bringing them up to speed. These are the key experts, ambassadors let them become very familiar with the product, use it in their facility. We’re going to put people on site to work with them. And as they become comfortable, they’re going to start teaching and rolling this out on our behalf. Then we will sign up the next cohort, the next cohort and the next cohort going forward. I want to do a little bit of a compare for you. Spark, the way rollout has taken place, now – some of the key experts in some geographies in Spain, as an example. Now they are creating its followership model that they train on their own, invite a large number of orthodontists, they see the value, they can show cases and they can see a migration and transition to Spark. Our goal with N1 is to replicate that model in 2022 in North America, we thoughtful, really diligent about how we want to go about it and manage in a safe environment, a cohort or a group of people that they can truly see the value of it, a step-up. Besides N1, our implant businesses, specifically Nobel, in Q4, premium impact grew double digit compared to 2020 and double digit compared to 2019. So our performance has improved significantly, and we are beginning to see and we have seen in the past six quarters, quarter-after-quarter better performance. I think N1 is just going to be an addition to what our team in North America in Europe and in China has been doing for us, which is getting this business to a high single-digit growth on an ongoing basis.

That’s great. That was very helpful. And just as a second question, and I might try to fit two in there, Howard, for you. More than 20% EBITDA margins, I just felt previously when you guys used to talk high teens, I mean, when you say more than 20, and you said talk 50 to 75 bps per annum, just maybe some clarity, like what does that mean? Is the 50 to 75 bps that you used to talk about intact off the 19.7%? And then admittedly a second – separate second question in there. Can you just get the Street comfortable with a mid-single-digit infection prevention long term? I think if there was any blemish in the quarter, it was just around Infection Prevention. Why the confidence you guys alluded to some of the sellout data. I know you’re going into new markets there, but why should we feel confident in that MSD long term? Thank you.

Sure, John. So let me go ahead and answer the first one as it relates to the EBITDA guide. We remain focused on delivering balanced performance. We’ve said that all along of accelerating growth while expanding our margins. In 2022, we’re raising our growth outlook and still expanding our margins. But we also are planning to make some pretty significant investments to sustain and certainly to ultimately accelerate our long-term growth. And so as you recall, at the time of IPO, we went from no growth to low single-digit growth to mid-single-digit growth, and now we’re taking it up to the single-digit plus growth and looking to even drive higher over the long term. And so certainly, the 50 to 75 basis points is something that we committed to on a per annual basis. We’ve driven over 400 bps of margin expansion in the last two years. We think that we want to be balanced in our approach, and we certainly want to go ahead and invest where we see the long-term growth and the opportunity. And so we’re taking advantage of that opportunity. And we’re still going to develop – deliver some margin expansion. Also keep in mind the reality of where we’re at today. We know that there is some inflationary factors that are impacting our business a little bit here as well. And so we want to be thoughtful and prudent about what we lay out for next year and for 2022.

Let me answer the IPS question. So we outlined the underlying macro drivers. So now the safety protocols is going to continue to exist and it’s going to be in place, and it’s a long-term trend, and it’s not going to change. We know that there are expansion of the offices, people are getting a lot more sophisticated on how they treat patients and go forward. So the underlying macro trends are there, and the business has been very focused on the dental. We have over 50% – up to about 60% market share in the dental in the U.S. and not a whole lot of presence in Europe as well as on the medical side. So combine those with what has been happening. If you look at the sellout on a sell-out basis, we continue to take share in dental. And we continue to see long-term growth opportunities in medical. What we saw in second half is a combination of overstock inventory. And not necessarily wasn’t all of our inventory. There was a little bit of a holding took place in 2020, demand pick. People need to kind of work through that inventory. The inventories are coming down. We are pretty confident that by Q2 second half this business is going to be back to what we expected to be normal, high profitability as well as mid-single-digit growth, what it used to be before COVID. With all the changes that we have done with the management effort consolidation of some of our activities, focus, EBS focus on the commercial, we think we have runway in this business. So we are committed, we’re confident that we can get this back on a mid-single-digit growth in high profitability part of our portfolio, most likely by second half, if not sooner.

That’s great color of both. Thanks guys.

Thank you.

We’ll take our next question from Erin Wright with Morgan Stanley. Please go ahead. Your line is open.

Great. Thanks. A follow-up on Spark here. Can you speak to the traction in U.S. versus international markets and how the broader international rollout is progressing? And how also you’re incorporating Spark into maybe some of your DSO relationships and the strategy on that front? Thanks.

Yes. Thank you, Erin. So – let me – the reason that the approach that we have taken is – I want to go back to our bracket and wire business. We have close to about 20% share. 70% of that business is outside U.S. We have significant presence in emerging markets in Europe. We have an incredible training and education program, and we have done a really good job. While everybody is moving away from that business, we just continue to take share in there. So we have said our first effort and Spark was just to go back to the true and tested customer base of Ormco. That was in the U.S., in Europe and now we’re signing, we’re registered and we’re going through the registration process, approval process. Geography by geography, specific even we are really strong in our base business of our Ormco. And the way we are approaching it is make sure that orthodontics and those that they have primarily focused in these procedures, see the value of the Spark and also see the value of a combination of the same company, giving them the competitive advantage, given the tools that they can become really productive. That has been our first approach. Then we’re sort of looking at, as you said, the DSOs. If you look at some of the new announcement that we have made, relationships with some of the largest DSOs in U.S. and Europe, they have a orthodontist capability inside those DSOs. Pacific, Vitaldent, they already do a large number of cases. They already use a large number of aligners. So – our focus on orthodontists and professional is not changing. We’re just expanding that. And last but not least, a lot of GPs now are coming to us and they’re asking to learn about a Spark as they are seeing the benefit of it as they’re learning and coming up to speed. So – as we had said, we’re not after direct to consumers, but for those that they are committed to the orthodontics segment, and they want to give people options, improve the quality of life, we’re there to help them to do better job to provide better services to their patients. And we’re going to follow that trend, and we think there is a significant amount of runway for us in that space.

Okay. Great. And in terms of M&A, can you speak to the pipeline at the moment and where the focus is, especially following your Carestream acquisition, what makes sense at this juncture?

Yes, happy to do it there. I mean we have outlined is sort of priority for us. And this is – honestly, it’s not a new thing. This is my year seven in dental. In the past seven years, we have been cultivating various companies. We have been analyzing the market, we are looking at various strengths. And what we are seeing, where there is an opportunity for differentiated solution in order to really improve patients’ life, it is an implant. And not necessarily only an implant itself from diagnostic all the way to prosthetics. In that space, we see opportunities for adding to our value implant portfolio, regenerative, prosthetic pieces and continue to add digital capabilities around AI, guided surgery, robotic navigated surgery. Look at the orthodontic space, ortho space, we see this combination of bracket and wire as well as clear aligner offer significant opportunity for us to become a lot more digitally capable. I want to put something in here. Last year, we put two new releases of a Spark out there. This year our intention is to really ramp that up to be the product of choice. In order to do that, we want to create an open platform that we can integrate other capabilities, other software tools, other AI tools, so we can give people choices, both on that two segment that we talked about. Ortho implant through digitally enabled workflow integration, that’s where we want to be focused on. We have been cultivating the company, working with company, and we’re going to continue to stay on that trend.

Great. Thank you.

We’ll take our next question from Nathan Rich with Goldman Sachs. Please go ahead. Your line is open.

Hi, good afternoon. Thanks for the questions. Howard, I maybe wanted to ask on the building blocks to the 6% to 8% organic growth. I think in 2021, the innovation products that you called out drove 300 basis points of growth last year. I guess, could you maybe talk about what you’re expecting from those products in 2022? And then going back to your comments on cadence kind of starting at mid-single-digit growth in the first quarter, it implied that you, I think, end the year at the high end or maybe even a bit above that 6% to 8% range. Is that just driven by the kind of effect of sequential growth in these products as they continue to ramp? Appreciate any details you could share around that.

Sure, Nate. So maybe for the first part of that question, consistent with what we’ve said and what we believe here as it relates to the guide for 2022, we think that the Spark and N1 will deliver at least north of 200, somewhere between 200 and 300 basis points of growth once again here in 2022. And so – and clearly, you’re going to see the mix up, as we said, in the specialty side as that growth has been, and we’ve enjoyed faster growth in that segment of the business. And so we’ll continue to see that as well. Bearing in mind again that this guidance does not contemplate the Carestream Dental IOS acquisition. So that’s the first piece. And then as it relates to phasing and the like, yes, we think that we see a little bit of slowdown here in the first quarter, and that’s why we see the mid-single-digit growth and it will ramp up to get us likely on the high end of that guide, it’s not slightly north of that by the end of the year. And we’ll see a steady, consistent improvement in growth quarter-over-quarter is the plan here.

Okay. Great. And then if I could ask on China. Could you maybe just go into a bit more detail on how it performed in the fourth quarter? I know you said it was below the 13% growth in emerging markets, but can you maybe just talk about what you saw in the fourth quarter? And so far here in the first quarter. And then related to that, I think you have Spark in China now as well. It’s a clear liner market that’s dominated by two players right now. I guess, what is the uptake of Spark been like in China as we think about that market opportunity? Thank you.

Sure. Happy to answer that, Nate. The China’s zero COVID policy is in place and continues to be in place. 15 providences hit various level of lockdown in Q4. And this Omicron continues to be an important factor, specifically given the Winter Olympics, travel and many other elements play a roll in. But let me break that down for you. Our specialty business, our implant and auto in the quarter was growing double digit and continues to – that trend continues as we have come through 2022. In – what we’re seeing in the consumable and equipment business, we saw a general weakness in there. And the decline was primarily in that segment and low single-digit decline. We expect that it’s going to continue weakness in Q1. But in long term, we think that we are really confident in what is taking place in China. We have a significant presence, there is underpenetrated opportunity there. We’re building – continue to build capabilities, manufacturing, marketing and sales, working with DSOs. Answering your question about Spark, we have been very thoughtful about priorities where we wanted to start building presence, building capabilities. We have the product already approved. We have not only from a clinical perspective, but also manufacturing capabilities in China. But this is a process that we have taken a step-by-step, geography by geography, make it successful, take the next one. That’s the approach that we are taking. Last part of that, Nate, is at every other geography. We’re not focused on the low-cost direct-to-consumers commodity-based. Our bracket and wire is growing rapidly in China, focus on the professional, medtech professional. And Spark is exactly positioned in that space. That’s where we want to be really in a good position. And we say we want to be the number 1 player in the dental space. That’s the space that we are focusing on, and we let the pull through. Those people teach it, establish it, show the outcome and it’s going to create a domino effect and network effect, and we’re going to see the outcome of that over time as we have seen in other geographies.

Thanks very much.

And in the interest of time, I’ll turn the program back to Mr. Stephen Keller for any closing comments.

Thank you, everyone, for your time today. We really appreciate it. If you have any questions, we’re here, happy to take any calls. But have a great afternoon, a great evening, and thank you for your time.

This does conclude today’s program. Thank you for your participation and you may now disconnect.